{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:06Z","timestamp":1790727066103,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.008","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T19:03:20Z","timestamp":1440097400000},"page":"731-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Natalie","family":"Spaccarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2015.05.008_bib1","first-page":"1","article-title":"Interferon treatment of human neoplasia","volume":"46","author":"Strander","year":"1986","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.det.2015.05.008_bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. the interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2015.05.008_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0002-9343(86)90360-8","article-title":"Alpha interferon in the treatment of hematologic malignancies","volume":"81","author":"Roth","year":"1986","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1993.tb01595.x","article-title":"Interferon treatment of cutaneous T-cell lymphoma","volume":"51","author":"Ross","year":"1993","journal-title":"Eur J Haematol"},{"issue":"11 SUPPL. 2","key":"10.1016\/j.det.2015.05.008_bib6","first-page":"S11","article-title":"Biologic response modifiers: the interferon alfa experience","volume":"46","author":"Koeller","year":"1989","journal-title":"Am J Hosp Pharm"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1440-0960.1980.tb00151.x","article-title":"The treatment of mycosis fungoides with PUVA","volume":"21","author":"Rotstein","year":"1980","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.det.2015.05.008_bib8","first-page":"25","article-title":"Antiproliferative action of interferons","volume":"2","author":"Tamm","year":"1987","journal-title":"Mechanisms of Interferon Actions"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2141.1992.tb08900.x","article-title":"Increase in 2',5'-oligoadenylate synthetase caused by deoxycoformycin in hairy cell leukaemia","volume":"80","author":"Ganeshaguru","year":"1992","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.det.2015.05.008_bib10","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.det.2015.05.008_bib12","series-title":"Physicians\u2019 desk reference","year":"2003"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib14","first-page":"255","article-title":"Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B","volume":"1","author":"Lai","year":"2006","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine TH2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.008_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1523-1747.ep12398454","article-title":"Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma","volume":"103","author":"Vowels","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/1523-1747.ep12330869","article-title":"Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA","volume":"107","author":"Asadullah","year":"1996","journal-title":"J\u00a0Invest Dermatol"},{"issue":"14","key":"10.1016\/j.det.2015.05.008_bib18","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib19","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1084\/jem.170.6.2081","article-title":"Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones","volume":"170","author":"Fiorentino","year":"1989","journal-title":"J\u00a0Exp Med"},{"issue":"13","key":"10.1016\/j.det.2015.05.008_bib20","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1073\/pnas.89.13.6065","article-title":"Differential regulation of T helper phenotype development by interleukins 4 and 10 in an a\u00df T-cell-receptor transgenic system","volume":"89","author":"Hsieh","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2004-03-1055","article-title":"Impaired CD40L signaling is a cause of defective IL-12 and TNF-\u03b1 production in S\u00e9zary syndrome: circumvention by hexameric soluble CD40L","volume":"105","author":"French","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.det.2015.05.008_bib22","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","article-title":"S\u00e9zary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines","volume":"100","author":"Wysocka","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1067\/mjd.2001.116345","article-title":"Complete molecular remission during biologic response modifier therapy for S\u00e9zary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity","volume":"45","author":"Yoo","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.det.2015.05.008_bib24","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","article-title":"Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15","volume":"104","author":"Wysocka","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"6117","key":"10.1016\/j.det.2015.05.008_bib26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/bmj.1.6117.920-d","article-title":"Serum IgE in mycosis fungoides","volume":"1","author":"Molin","year":"1978","journal-title":"Br Med J"},{"issue":"9","key":"10.1016\/j.det.2015.05.008_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archderm.140.9.1057","article-title":"Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas","volume":"140","author":"Tancr\u00e8de-Bohin","year":"2004","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.det.2015.05.008_bib29","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and S\u00e9zary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"J\u00a0Am Med Assoc"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(81)70021-5","article-title":"An unusual and fatal case of disseminated cutaneous herpes simplex. Infection in a patient with cutaneous T cell lymphoma (mycosis fungoides)","volume":"4","author":"Goldgeier","year":"1981","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mjd.2001.109853","article-title":"Increased interleukin 5 production in eosinophilic S\u00e9zary syndrome: regulation by interferon alfa and interleukin 12","volume":"44","author":"Suchin","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3\u20134","key":"10.1016\/j.det.2015.05.008_bib32","first-page":"413","article-title":"T\u00a0cell and cytokine patterns in leprosy skin lesions","volume":"13","author":"Sieling","year":"1992","journal-title":"Springer Semin Immunopathol"},{"issue":"5","key":"10.1016\/j.det.2015.05.008_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0889-8588(18)30054-6","article-title":"The immunopathogenesis of cutaneous T-cell lymphoma","volume":"9","author":"Rook","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"10.1016\/j.det.2015.05.008_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM198710083171506","article-title":"Current concepts: lymphokines","volume":"317","author":"Dinarello","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","article-title":"Interferons in the treatment of human cancer","volume":"2","author":"Kirkwood","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.det.2015.05.008_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF02505252","article-title":"Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA","volume":"288","author":"Rajan","year":"1996","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-\u03b1 resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"S\u00e9zary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the united states cutaneous lymphoma consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.008_bib41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/archderm.1977.01640040062009","article-title":"Recombinant interferon alfa-2b in plaque-phase mycosis fungoides","volume":"113","author":"Vonderheid","year":"1977","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib42","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0190-9622(85)70205-8","article-title":"Intralesional interferon in the treatment of early mycosis fungoides","volume":"13","author":"Wolff","year":"1985","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2133.1989.tb15526.x","article-title":"Low-dose recombinant interferon-\u03b1 in the treatment of cutaneous T-cell lymphomas","volume":"121","author":"Dreno","year":"1989","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.1988.tb02600.x","article-title":"Treatment of mycosis fungoides with recombinant interferon-\u03b12a2 alone and in combination with etretinate","volume":"118","author":"Thestrup-Pedersen","year":"1988","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.det.2015.05.008_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.1991.tb08119.x","article-title":"Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?","volume":"79","author":"Papa","year":"1991","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib46","first-page":"337","article-title":"Alpha recombinant interferon in the treatment of mycosis fungoides (MF)","volume":"72","author":"Tura","year":"1987","journal-title":"Haematologica"},{"issue":"8 SUPPL","key":"10.1016\/j.det.2015.05.008_bib47","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"issue":"SUPPL 4","key":"10.1016\/j.det.2015.05.008_bib48","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/0277-5379(91)90569-Y","article-title":"Role of interferon alfa-2b in the management of patients with advanced cutaneous T-cell lymphoma","volume":"27","author":"Mughal","year":"1991","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.det.2015.05.008_bib49","unstructured":"PegIntron [package insert]. Kenilworth, NJ: Schering-Plough; 2013."},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S\u00e9zary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.008_bib52","first-page":"549","article-title":"Treatment of cutaneous T-cell lymphoma with recombinant alfa 2B interferon","volume":"93","author":"Estrach","year":"1989","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2015.05.008_bib53","unstructured":"Dallot A, Feyeux C, Gorin I. Interferon treatment in cutaneous lymphomas. Proceedings of the International Society of Haematology Conference. 1988. p. 267."},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000248098","article-title":"Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a","volume":"179","author":"Nicolas","year":"1989","journal-title":"Dermatologica"},{"key":"10.1016\/j.det.2015.05.008_bib55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-3-642-78771-3_30","article-title":"Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy","volume":"139","author":"Stadler","year":"1995","journal-title":"Recent Results Cancer Res"},{"issue":"10","key":"10.1016\/j.det.2015.05.008_bib56","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon \u03b1-2a plus acitretin versus interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib57","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-\u03b1-2a plus psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib58","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1468-3083.2010.03732.x","article-title":"PUVA plus interferon a2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series","volume":"25","author":"Nikolaou","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib59","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-a and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2008.08886.x","article-title":"Psoralen plus ultraviolet A \u00b1 interferon-\u03b1 treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-\u03baB and T-cell receptor pathways","volume":"160","author":"Wozniak","year":"2009","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.008_bib61","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ctrv.2014.06.005","article-title":"Systematic review of combination therapies for mycosis fungoides","volume":"40","author":"Humme","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-3083.2011.04011.x","article-title":"Comparison of pegylated interferon a-2b plus psoralen PUVA versus standard interferon a-2a plus PUVA in patients with cutaneous T-cell lymphoma","volume":"26","author":"H\u00fcsken","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.det.2015.05.008_bib63","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2003.10.669","article-title":"Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms","volume":"50","author":"McGinnis","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2I","key":"10.1016\/j.det.2015.05.008_bib65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib66","first-page":"580","article-title":"Treatment of mycosis fungoides with recombinant alpha 2B interferon in combination with etretinate","volume":"93","author":"Stavrianeas","year":"1989","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9070","key":"10.1016\/j.det.2015.05.008_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(05)66242-3","article-title":"Extracorporeal photopheresis and interferon-\u03b1 in advanced cutaneous T-cell lymphoma","volume":"350","author":"Dippel","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mjd.2001.110645","article-title":"Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial","volume":"44","author":"Wollina","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2015.05.008_bib69","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archderm.139.7.909","article-title":"Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy","volume":"139","author":"Ferenczi","year":"2003","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.det.2015.05.008_bib70","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/archderm.1991.01680090099012","article-title":"Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations","volume":"127","author":"Rook","year":"1991","journal-title":"Arch Dermatol"},{"issue":"5 II","key":"10.1016\/j.det.2015.05.008_bib71","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0190-9622(99)70351-8","article-title":"Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis","volume":"41","author":"Haley","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000421-199406000-00016","article-title":"Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome: use of dual marker labeling to monitor therapeutic response","volume":"17","author":"Vonderheid","year":"1994","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib73","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1067\/mjd.2000.105163","article-title":"Evidence is lacking for a synergistic or additive effect of combination extracorporeal photopheresis with interferon alfa for cutaneous T-cell lymphoma","volume":"42","author":"Zackheim","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2015.05.008_bib74","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archdermatol.2011.232","article-title":"High clinical response rate of S\u00e9zary syndrome to immunomodulatory therapies: prognostic markers of response","volume":"147","author":"Raphael","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2006.07559.x","article-title":"Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?","volume":"156","author":"Roberge","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib76","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjd.12386","article-title":"Mycosis fungoides: the addition of concurrent and adjuvant interferon to total skin electron beam therapy","volume":"169","author":"Wagner","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.008_bib77","series-title":"Apoptosis and cutaneous T cell lymphoma","year":"2001"},{"issue":"12","key":"10.1016\/j.det.2015.05.008_bib78","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.det.2015.05.008_bib79","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib80","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/cbr.2007.0402","article-title":"Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides\/S\u00e9zary syndrome","volume":"22","author":"Avil\u00e9s","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.det.2015.05.008_bib81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.abb.2014.04.019","article-title":"Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas\/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy","volume":"563","author":"Nihal","year":"2014","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.det.2015.05.008_bib82","first-page":"403","article-title":"The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and S\u00e9zary syndrome","volume":"10","author":"Sanli","year":"2011","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib83","first-page":"428","article-title":"Combination therapy with extracorporeal photopheresis, interferon-a, PUVA and topical corticosteroids in the management of S\u00e9zary syndrome","volume":"8","author":"Booken","year":"2010","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib84","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1046\/j.1365-2133.1999.02889.x","article-title":"Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sezary syndrome","volume":"140","author":"Fritz","year":"1999","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib85","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3816\/CLM.2006.n.063","article-title":"High clinical response rate with multimodality immunomodulatory therapy for S\u00e9zary syndrome","volume":"7","author":"Richardson","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib86","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/08916930903510963","article-title":"Interferon-a as angiogenesis inhibitor: learning from tumor models","volume":"43","author":"Indraccolo","year":"2010","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.det.2015.05.008_bib88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0676.1997.tb00788.x","article-title":"Interferon-alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis","volume":"17","author":"Kadayifci","year":"1997","journal-title":"Liver"},{"key":"10.1016\/j.det.2015.05.008_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of interferon-\u03b3","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.det.2015.05.008_bib90","unstructured":"Actimmue [package insert]. Roswell, GA: Vidara Therapeutics; 2013."},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib91","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib92","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-\u03b3 gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib93","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/1346-8138.12341","article-title":"Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides","volume":"41","author":"Sugaya","year":"2014","journal-title":"J\u00a0Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.05.008_bib94","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archderm.141.9.1176","article-title":"The addition of interferon gamma to oral bexarotene therapy with photopheresis for S\u00e9zary syndrome","volume":"141","author":"McGinnis","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.008_bib95","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaad.2008.11.889","article-title":"A\u00a0novel regimen of vorinostat with interferon gamma for refractory S\u00e9zary syndrome","volume":"61","author":"Gardner","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.008_bib96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jdermsci.2007.12.004","article-title":"Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-\u03b3 and narrowband UVB in patients with mycosis fungoides","volume":"50","author":"Shimauchi","year":"2008","journal-title":"J\u00a0Dermatol Sci"},{"issue":"6","key":"10.1016\/j.det.2015.05.008_bib97","first-page":"547","article-title":"Beta interferon in the treatment of mycosis fungoides","volume":"73","author":"Zinzani","year":"1988","journal-title":"Haematologica"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T11:09:33Z","timestamp":1599476973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000534"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}